Effects of prednisolone on angiotensin converting enzyme activity. 1984

J E Roulston, and G I O'Malley, and J G Douglas

Plasma angiotensin converting enzyme was measured in 23 asthmatic subjects before and after administration of prednisolone, 20 mg daily, for seven days. Plasma specimens from seven patients with asthma, seven with sarcoidosis and 14 normal subjects were also assayed before and after the addition of prednisolone in vitro. A plasma free extract of normal lung was also prepared and assayed before and after prednisolone treatment. Mean angiotensin converting enzyme activity was significantly greater in the asthmatic patients (40.3 nmol min-1 ml plasma-1) than in the control population (35.1 nmol min-1 ml plasma-1), though remaining within the 95% reference range. A fall in plasma angiotensin converting enzyme levels was seen after the addition of prednisolone in asthmatics both in vivo and in vitro. Similar in vitro falls were seen in patients with sarcoidosis but not in controls or in normal lung extract. No changes in angiotensin converting enzyme activity were seen after a single dose of 20 mg prednisolone in normal volunteers. Patients with asthma therefore appear to have higher mean angiotensin converting enzyme activities than the normal population and these fall after the addition of prednisolone whether this is added in vivo or in vitro.

UI MeSH Term Description Entries
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D008171 Lung Diseases Pathological processes involving any part of the LUNG. Pulmonary Diseases,Disease, Pulmonary,Diseases, Pulmonary,Pulmonary Disease,Disease, Lung,Diseases, Lung,Lung Disease
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D012507 Sarcoidosis An idiopathic systemic inflammatory granulomatous disorder comprised of epithelioid and multinucleated giant cells with little necrosis. It usually invades the lungs with fibrosis and may also involve lymph nodes, skin, liver, spleen, eyes, phalangeal bones, and parotid glands. Besnier-Boeck Disease,Boeck's Sarcoid,Besnier-Boeck-Schaumann Syndrome,Boeck Disease,Boeck's Disease,Schaumann Disease,Schaumann Syndrome,Schaumann's Syndrome,Besnier Boeck Disease,Besnier Boeck Schaumann Syndrome,Boeck Sarcoid,Boecks Disease,Boecks Sarcoid,Disease, Schaumann,Sarcoid, Boeck's,Sarcoidoses,Schaumann's Syndromes,Syndrome, Besnier-Boeck-Schaumann,Syndrome, Schaumann,Syndrome, Schaumann's

Related Publications

J E Roulston, and G I O'Malley, and J G Douglas
January 1992, Clinical and experimental pharmacology & physiology. Supplement,
J E Roulston, and G I O'Malley, and J G Douglas
August 2002, Peptides,
J E Roulston, and G I O'Malley, and J G Douglas
July 1990, Clinical science (London, England : 1979),
J E Roulston, and G I O'Malley, and J G Douglas
March 1991, American journal of hypertension,
J E Roulston, and G I O'Malley, and J G Douglas
April 1986, Clinical chemistry,
J E Roulston, and G I O'Malley, and J G Douglas
December 1993, Clinical science (London, England : 1979),
J E Roulston, and G I O'Malley, and J G Douglas
January 1987, Clinical science (London, England : 1979),
J E Roulston, and G I O'Malley, and J G Douglas
January 1986, Plucne bolesti : casopis Udruzenja pneumoftiziologa Jugoslavije = the journal of Yugoslav Association of Phthisiology and Pneumology,
J E Roulston, and G I O'Malley, and J G Douglas
October 1992, The American journal of cardiology,
J E Roulston, and G I O'Malley, and J G Douglas
January 2003, Hypertension research : official journal of the Japanese Society of Hypertension,
Copied contents to your clipboard!